Key facts
- It has raised $150K; the latest was Angel (individual) ($150K) in Dec 2025.
- Cyana Therapeutics has filed 1 Form D with the SEC, most recently Dec 2025 ($151K sold to 12 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Cyana Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cyana Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cyana Therapeutics
Provider of immuno-oncology therapies designed for patients to restore the body's natural anti-cancer immune response. The company's therapies offer extended drug-target residence time, block ENPP1, which is often upregulated in cancers of the liver, pancreas, breast, and lungs, enabling oncologists to transform tumors into immune-activating ones.
- Sector
- Healthcare
- HQ
- Miami Beach, FL, United States
- Founded
- 2025
- Website
- cyanatx.com/
- Ownership
- Privately Held (backing)
Cyana Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cyana Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cyana Therapeutics in its N-PORT filings yet. We sweep new filings monthly.